Human — controlled trial

Early-phase human work on thymosin beta-4

Placeholder seed record. A small number of early-phase human studies of the parent protein exist in the listed literature. None were carried through to marketing approval in any jurisdiction, and none concern the TB-500 fragment as sold.

Cited by

TB-500
What the research on TB-500 actually shows
Almost all literature cited for TB-500 concerns thymosin beta-4, the full parent protein — not the fragment sold under the TB-500 name. This distinction is the whole story for this compound. A vendor citing thymosin beta-4 research on a TB-500 product page is citing work about a different molecule, and the indexed literature contains no controlled human trial of the fragment as sold.

Compounds examined

TB-500

Study records state what a paper reported. PepIndex does not interpret findings, assess clinical significance, or restate results in language implying an application not present in the source. Last reviewed 23 Jul 2026.